MOBAN Drug Patent Profile

Which patents cover Moban, and when can generic versions of Moban launch?

Moban is a drug marketed by Chartwell Rx and Endo Pharms and is included in two NDAs.

The generic ingredient in MOBAN is molindone hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the molindone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Moban

A generic version of MOBAN was approved as molindone hydrochloride by EPIC PHARMA LLC on March 20^th, 2015.

Summary for MOBAN

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for MOBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	MOBAN	molindone hydrochloride	CAPSULE;ORAL	017111-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Endo Pharms	MOBAN	molindone hydrochloride	CONCENTRATE;ORAL	017938-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-007	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Chartwell Rx	MOBAN	molindone hydrochloride	CAPSULE;ORAL	017111-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

MOBAN Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Investment Outlook for MOBAN (Molindone)?

MOBAN (molindone) is a dopamine antagonist primarily developed for schizophrenia treatment. Its market prospects are unaffected by recent FDA approvals or withdrawals. Since it lacks recent patent protections and faces competition from newer atypical antipsychotics, it largely functions as a niche or off-label therapy.

What Are the Fundamental Characteristics of MOBAN?

Patent and Regulatory Status

• Patent Status: Molindone's patent expired in the early 2000s. No new patents have been filed, limiting exclusivity and commercial lifespan.
• Regulatory Approval: Approved in the US in the 1970s. Withdrawn from some markets due to safety concerns or market shifts, though still available in select countries.

Market Position and Usage

• Market Penetration: Limited in major markets; used historically in schizophrenia management but replaced largely by atypical antipsychotics like risperidone or olanzapine.
• Off-label Use: Sometimes used off-label for psychosis or agitation but with limited evidence.

Competitive Landscape

Drug Class	Key Drugs	Market Share	Notes
Atypical Antipsychotics	Risperidone, olanzapine, quetiapine	> 80%	Dominates schizophrenia treatment
Typical Antipsychotics	Haloperidol, chlorpromazine	Declining	Limited use due to side-effect profile
Molindone (MOBAN)	Moderate, outdated, niche use	Minimal	No recent innovation or pipeline

Sales and Revenue

• Sales Trend: Historically modest. Limited sales in the US and Europe. Without patent protection, marketing incentives diminish.
• Market Size: Schizophrenia drugs estimated at over $10 billion annually worldwide, but MOBAN’s share is minimal (<1%).

Safety and Side Effects

• Adverse Effects: Higher rates of weight gain, metabolic syndrome, and extrapyramidal symptoms compared to atypicals.
• Regulatory Concerns: Some markets limited or withdrew approval due to safety concerns; safety profile less favorable compared to newer drugs.

What Are the Core Investment Risks?

• Market Obsolescence: Replaced by newer agents with better safety and efficacy profiles.
• Patent Expiry: No active patent protections to prevent generic competition.
• Limited Pipeline: No ongoing clinical trials or formulations, reducing future growth prospects.
• Regulatory Trends: Increasing restrictions on older drugs with adverse side effects.

What Are the Opportunities for Niche or Off-Label Use?

• Off-Label Applications: Some clinicians may prescribe for rare psychosis or agitation, but this off-label use remains limited.
• Market Opportunities: Little room for expansion without significant reformulation or repositioning.

Are There Any Potential Acquisition or Licensing Opportunities?

• Unlikely: The drug's obsolescence diminishes acquisition interest.
• Small-scale Licensing: Some niche markets or research institutions may be interested for research purposes, but commercial prospects are slim.

Key Takeaways

• MOBAN (molindone) has no active patent protection, with a sales trajectory that has declined significantly since the 2000s.
• Its safety profile and market position are weaker compared to newer atypical antipsychotics.
• The medication operates in a shrinking niche, with limited commercial growth potential.
• The risk profile for investment is high, with minimal prospects for renewal or expansion.
• Licensing or off-label use offers negligible upside for large-scale investment.

FAQ

1. Is MOBAN still commercially viable?
No. Its market presence is minimal, and it faces substantial competition from newer drugs.

2. Are there opportunities to develop new formulations of MOBAN?
Likely not. The drug's safety profile and obsolescence reduce interest in reformulation efforts.

3. Have regulatory agencies withdrawn MOBAN from any markets?
Some markets have limited or withdrawn approval due to safety concerns; it remains largely available in select regions.

4. Can MOBAN be repurposed for other indications?
Current evidence does not support significant alternative indications; research is limited.

5. What is the future outlook for MOBAN?
Limited. The drug is unlikely to see growth absent major reformulation or repositioning initiatives.

---

References

[1] IMS Health. "Global Schizophrenia Treatment Market Analysis," 2021.
[2] FDA. "Molindone (MOBAN) Product Information," 1980s-2000s.
[3] IQVIA. "Pharmaceutical Market Data," 2022.